In this article, we will be taking a look at the 10 most undervalued healthcare stocks to buy according to analysts. 

The CEO of Pivotal Advisors, Tiffany McGhee, spoke on CNBC on June 27 on what investors should do in light of the current state of the market. In order to stay in line with long-term objectives, she added that investors should reassess allocations, reduce hot spots, and strengthen underweight areas as the market moves into the second half of 2025. She went on to say that diversification is still the greatest way to guard against uncertainty and prepare for future market trends.

In the same interview, Meghan Shue, Head of Investment Strategy at Wilmington Trust, also expressed her opinion, saying that even though the market might experience some volatility into the summer, investors should remain invested because there is a lot of potential in the tech sector as well as some of the other, more established industries, like the healthcare sector, which has historically been a segment of the market that no one has wanted to enter.

McGhee supported this claim by stating that she anticipates possibilities for catch-up in the healthcare industry. Keeping these trends in mind, let’s look at the 10 most undervalued healthcare stocks to buy according to analysts.

Our Methodology  

For our methodology, we used a stock screener to filter companies with a P/E ratio under 15 and high analyst upside. The final list was ranked by highest analyst upside to identify undervalued stocks with strong growth potential.

Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 373.4% since May 2014, beating its benchmark by 218 percentage points (see more details here).

Here is our list of the 10 most undervalued healthcare stocks to buy according to analysts.

10. Bio-Rad Laboratories, Inc. (NYSE:BIO)

Analyst Upside: 324.25%

Bio-Rad Laboratories, Inc. (NYSE:BIO) is one of the most undervalued healthcare stocks. It is a global leader in life science research and clinical diagnostics and advanced its digital PCR capabilities in 2025 with the launch of four new Droplet Digital PCR (ddPCR) instruments, including the QX Continuum and QX700 series, acquired through its purchase of Stilla Technologies. These systems significantly expand the company’s ddPCR portfolio, now offering over 400,000 assays, and enhance applications in oncology, infectious disease, and genetic analysis through improved multiplexing, throughput, and workflow integration.

Supporting the growing field of gene therapy, Bio-Rad Laboratories, Inc. (NYSE:BIO) released ddPCR kits for accurate measurement of adeno-associated virus (AAV) vectors, enabling efficient viral titer and capsid integrity assessment. The company also extended its Vericheck kits to support additional viral serotypes for broader biotherapeutic research.

The corporation’s other key product launches include the TrailBlazer Tag and StarBright Dye Label kits for antibody conjugation in flow cytometry and Western blotting, and new purification tools—Nuvia wPrime 2A resin and Foresight Pro columns, designed for scalable biopharma manufacturing.

Throughout 2025, Bio-Rad Laboratories, Inc. (NYSE:BIO) has remained actively engaged in global industry events, offering workshops on diagnostic innovation and showcasing its expanding technology portfolio for both clinical and research applications.

9. BeOne Medicines Ltd. (NASDAQ:ONC)

Analyst Upside: 332.44%

BeOne Medicines Ltd. (NASDAQ:ONC), formerly BeiGene, is a global oncology company now headquartered in Switzerland following its May 2025 redomiciliation. The strategic move enhances the company’s access to European biotech networks and regulatory alignment, supporting its mission to lead in cancer innovation. With operations in over 45 countries and a pipeline of 50+ investigational assets, the business is rapidly expanding its R&D and clinical presence.

A major milestone for BeOne Medicines Ltd. (NASDAQ:ONC) this year was the European Commission’s approval of Tevimbra (tislelizumab) for multiple indications, including extensive-stage small cell lung cancer and nasopharyngeal carcinoma, further cementing its role in immuno-oncology. Tevimbra is already FDA-approved for esophageal cancer, and continued regulatory momentum is expected.

In hematology, the corporation showcased significant advances at the 2025 EHA Congress. Sonrotoclax (a BCL2 inhibitor) and BGB-16673 (a first-in-class BTK degrader) delivered promising results in treating resistant forms of chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL), advancing toward Phase 3 trials. Meanwhile, BRUKINSA (zanubrutinib) remains a core therapy, demonstrating superior outcomes compared to ibrutinib.

BeOne Medicines Ltd. (NASDAQ:ONC) also made strides in pipeline growth, advancing 13 new molecules into clinical trials in 2024 alone. With 170+ global trials and over 25,000 patients enrolled, its “Fast to Proof-of-Concept” strategy accelerates timelines and patient access. In June 2025, a licensing deal with Neowise Biotechnology expanded the business’s efforts in next-gen cell therapies, particularly TCR-based platforms.